Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HYALURONIDASE ADDITIONAL TO STANDARD CHEMOTHERAPY IMPROVES OUTCOME FOR CHILDREN WITH MALIGNANT BRAIN-TUMORS
Autore:
PILLWEIN K; FUIKO R; SLAVC I; CZECH T; HAWLICZEK G; BERNHARDT G; NIRNBERGER G; KOLLER U;
Indirizzi:
DEUTSCH ORDENS SPITAL,FORSCHUNGSGESELL CEREBRALE TUMORE,ST VEITERSTR 12 A-9360 FRIESACH AUSTRIA UNIV HOSP VIENNA,AKH,DEPT PEDIAT NEUROONCOL A-1090 VIENNA AUSTRIA UNIV HOSP VIENNA,AKH,DEPT NEUROSURG A-1090 VIENNA AUSTRIA UNIV HOSP VIENNA,AKH,DEPT RADIAT THERAPY A-1090 VIENNA AUSTRIA UNIV REGENSBURG,INST PHARMACEUT D-8400 REGENSBURG GERMANY SFI,INST BIOMETRY & STAT VIENNA AUSTRIA LKH KLAGENFURT,DEPT CLIN CHEM & LAB MED KLAGENFURT AUSTRIA
Titolo Testata:
Cancer letters
fascicolo: 1, volume: 131, anno: 1998,
pagine: 101 - 108
SICI:
0304-3835(1998)131:1<101:HATSCI>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
MELANOMA;
Keywords:
HYALURONIDASE; BRAIN TUMORS; CHILDREN; RELAPSE; MEDULLOBLASTOMA; EPENDYMOBLASTOMA; MAFOSFAMIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
12
Recensione:
Indirizzi per estratti:
Citazione:
K. Pillwein et al., "HYALURONIDASE ADDITIONAL TO STANDARD CHEMOTHERAPY IMPROVES OUTCOME FOR CHILDREN WITH MALIGNANT BRAIN-TUMORS", Cancer letters, 131(1), 1998, pp. 101-108

Abstract

Ex vivo experiments with vital brain tumor samples I;how that hyaluronidase enhances the permeation of carboplatin into tumor tissue with amatrix rich in hyaluronic acid. We achieved long-lasting second remissions for children with relapsed malignant brain tumors treated with carboplatin, etoposide and this enzyme. Thereafter, we initiated a pilot study where we added hyaluronidase to the first line standard therapy to prevent the deadly relapses right from the beginning. All 19 patients with malignant brain tumors admitted to our pediatric neurooncological center from 1992 to 1994 were included in the study. Kaplan-Meier estimation of event-free survival and overall survival after 3 yearsfollow-up indicates a significantly better outcome for the hyaluronidase-treated group. The children receiving supportive hyaluronidase suffered significantly less relapses (P = 0.034) and had a significantly better chance for survival (P = 0.045) compared to the historical control of 21 children treated with the same standard regimen but without supportive hyaluronidase (product limit analysis and the log-rank test, P < 0.05). Children aged >3 years receiving hyaluronidase together with primary treatment seemed to gain the most benefit. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 10:17:06